<?xml version="1.0" encoding="UTF-8"?>
<p id="Par46">Many companies have departments for corporate social responsibility with whom innovative partnerships could be forged [
 <xref ref-type="bibr" rid="CR15">15</xref>, 
 <xref ref-type="bibr" rid="CR36">36</xref>]; for viral hepatitis an example of an approach could be that a pharmaceutical company foundation subsidizes the cost of hepatitis medication for members of a national health insurance scheme, under which hepatitis prevention and treatment protocols are tested while offered as covered services. The partners learn together about disease burden and how to identify/treat patients cost-effectively, although the cost-effectiveness analyses would need to take into consideration the possibility of re-infection after successful treatment [
 <xref ref-type="bibr" rid="CR37">37</xref>, 
 <xref ref-type="bibr" rid="CR38">38</xref>]. There could be a sliding scale for price of medicines based on volume, providing a shared incentive to bring a programme to scale.
</p>
